Larsson J, Hultberg B, Hillarp A
Department of Ophthalmology, Lund University Hospital, Sweden.
Acta Ophthalmol Scand. 2000 Jun;78(3):340-3. doi: 10.1034/j.1600-0420.2000.078003340.x.
Hyperhomocysteinemia is a factor that predisposes to thrombosis, and the C677T mutation in methylene-tetrahydrofolate reductase (MTHFR) is known to give increased plasma homocysteine. We wanted to investigate if these factors were overrepresented in a group of patients with central retinal vein occlusion.
116 patients with a history of central retinal vein occlusion were examined for the presence of hyperhomocysteinemia and the MTHFR C677T mutation.
Compared to the control groups, there was no significant increase, neither in plasma homocysteine nor in the frequency of the MTHFR C677T mutation in the patients. Even when we looked selectively at the young patients, age less than 50 years, no difference could be detected.
It seems that neither hyperhomocysteinemia nor the MTHFR C677T mutation is an important risk factor for the aetiology of central retinal vein occlusion.
高同型半胱氨酸血症是易导致血栓形成的一个因素，已知亚甲基四氢叶酸还原酶（MTHFR）的C677T突变会使血浆同型半胱氨酸水平升高。我们想要研究这些因素在一组视网膜中央静脉阻塞患者中是否比例过高。
对116例有视网膜中央静脉阻塞病史的患者进行高同型半胱氨酸血症及MTHFR C677T突变检测。
与对照组相比，患者的血浆同型半胱氨酸水平及MTHFR C677T突变频率均无显著升高。即使我们选择性地观察年龄小于50岁的年轻患者，也未发现差异。
看来高同型半胱氨酸血症和MTHFR C677T突变均不是视网膜中央静脉阻塞病因的重要危险因素。
